14 November 2018 - Ottawa wants to apply new price regulations, which will only cut manufacturer profits and deter the introduction of new medicines here.

The Patented Medicine Prices Review Board is the federal government agency that regulates the prices of patented medicines in Canada. Its mandate is to ensure that the prices for patented medicines are not excessive. The Liberal government has proposed sweeping changes for the price review guidelines used by the board. 

There is mounting evidence that the changes will be bad for Canadian patients. The revisions are currently working their way through the final stages of the legislative process and are due to come into effect in 2019. But, there is still an opportunity for the government to walk back from this.

Read Financial Post article